Compile Data Set for Download or QSAR
Report error Found 681 Enz. Inhib. hit(s) with all data for entry = 2549
TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371055(US10239843, Example 162)
Affinity DataIC50: 4nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371063(US10239843, Example 170)
Affinity DataIC50: 6nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371355(US10239843, Example 463 | 1-[(2,4-Dimethylthiazol-...)
Affinity DataIC50: 6nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371463(US10239843, Example 572 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 7nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371294(US10239843, Example 401 | N-(1-Cyanocyclopropyl)-1...)
Affinity DataIC50: 8nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371454(US10239843, Example 563 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 8nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371470(US10239843, Example 579 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 9nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371469(US10239843, Example 578 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 10nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371267(US10239843, Example 374)
Affinity DataIC50: 11nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371289(US10239843, Example 396 | 1-[(2,4-Dimethylthiazol-...)
Affinity DataIC50: 11nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371056(US10239843, Example 163)
Affinity DataIC50: 12nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371519(N-[1-(Fluoromethyl)cyclopropyl]-1-[(1-methylpyrazo...)
Affinity DataIC50: 16nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371506(1-[(2,4-Dimethylthiazol-5-yl)methyl]-N-[1-(fluorom...)
Affinity DataIC50: 17nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371066(US10239843, Example 173)
Affinity DataIC50: 18nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371049(US10239843, Example 156)
Affinity DataIC50: 19nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371479(US10239843, Example 588 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 19nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371268(US10239843, Example 375)
Affinity DataIC50: 20nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371330(US10239843, Example 437 | 1-[(2,5-Dimethylpyrazol-...)
Affinity DataIC50: 23nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371334(US10239843, Example 441 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 24nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371284(US10239843, Example 391 | 7-Fluoro-N-(1-methylcycl...)
Affinity DataIC50: 24nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371468(US10239843, Example 577 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 24nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371281(US10239843, Example 388 | N-(1-Cyanocyclopropyl)-7...)
Affinity DataIC50: 25nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371485(US10239843, Example 594 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 25nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371293(US10239843, Example 400 | N-(1-Cyanocyclopropyl)-1...)
Affinity DataIC50: 27nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371286(US10239843, Example 393 | 7-Fluoro-N-(1-methylcycl...)
Affinity DataIC50: 28nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371494(US10239843, Example 603 | 1-[(2,5-Dimethylpyrazol-...)
Affinity DataIC50: 29nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371382(US10239843, Example 490 | 1-[(2,5-Dimethylpyrazol-...)
Affinity DataIC50: 29nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371067(US10239843, Example 174)
Affinity DataIC50: 29nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371482(US10239843, Example 591 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 30nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371481(US10239843, Example 590 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 30nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371292(US10239843, Example 399 | N-(1-Cyanocyclopropyl)-1...)
Affinity DataIC50: 31nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371058(US10239843, Example 165)
Affinity DataIC50: 33nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371439(US10239843, Example 548 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 34nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371272(US10239843, Example 379)
Affinity DataIC50: 35nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371101(US10239843, Example 208)
Affinity DataIC50: 36nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371476(US10239843, Example 585 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 38nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371100(US10239843, Example 285 | US10239843, Example 207)
Affinity DataIC50: 38nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371455(US10239843, Example 564 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 38nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371507(1-Butyl-N-[1-(fluoromethyl)cyclopropyl]-3-[(1-meth...)
Affinity DataIC50: 39nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371353(US10239843, Example 461 | 1-(Cyclobutylmethyl)-N-[...)
Affinity DataIC50: 39nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371310(US10239843, Example 417 | 1-(Cyclopropylmethyl)-N-...)
Affinity DataIC50: 40nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371349(US10239843, Example 457 | N-(1-Cyanocyclopropyl)-1...)
Affinity DataIC50: 42nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371467(US10239843, Example 576 | 1-[(3-Ethylimidazol-4-yl...)
Affinity DataIC50: 42nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371503(US10239843, Example 613 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 42nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371252(US10239843, Example 359)
Affinity DataIC50: 43nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371335(US10239843, Example 442 | N-[1-(Fluoromethyl)cyclo...)
Affinity DataIC50: 43nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371271(US10239843, Example 378)
Affinity DataIC50: 44nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371291(US10239843, Example 398 | 7-Fluoro-3-((1-methyl-1H...)
Affinity DataIC50: 44nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371054(US10239843, Example 161)
Affinity DataIC50: 45nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM371285(US10239843, Example 392 | 1-[(2,5-Dimethylpyrazol-...)
Affinity DataIC50: 47nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
US Patent

Displayed 1 to 50 (of 681 total ) | Next | Last >>
Jump to: